Clinical Trial Update: A Study of Safety and Efficacy Comparing ABT-874 Versus Methotrexate in Subjects With Moderate to Severe Plaque Psoriasis [Phase 3]

View source ↗

Summary

Phase 3 study comparing ABT-874 with methotrexate in subjects with moderate to severe plaque psoriasis has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Plaque Psoriasis

Drugs mentioned

• ABT-874 (briakinumab)
• METHOTREXATE (METHOTREXATE)

Snippet

Sponsor: AbbVie (prior sponsor, Abbott) | Conditions: Psoriasis | Phase 3 | Status: COMPLETED